Trend of circulating CD34⁺ cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment

Abstract

ABL1-negative myeloproliferative neoplasms (MPNs) are already known to be variably characterised by an increase in peripheral blood (PB) and bone marrow (BM) progenitor cells. More specifically, in patients with myelofibrosis (MF) it has already been reported that the number of circulating haematopoietic precursors is consistently high, with a relative circulating CD34 + cells count of 0.015 × 10 9 /L as the most frequently used criterion to discriminate between MF and other MPNs. 1 According to the 2016 World Health Organization (WHO) classification, primary MF (PMF) is defined as a haematopoietic stem-cell-derived clonal disorder, 2 in which the abnormal stem cell population releases various cytokines and growth factors in the BM microenvironment. 3 It can be subcategorised into pre-fibrotic and overt fibrotic PMF depending on specific features. 4 Furthermore, MF can also represent an advanced stage during the natural history of another pre-existing BCR::ABL1-negative MPN, namely polycythaemia vera (PV) or essential

Lentiviral gene therapy reverts GPIX expression and phenotype in Bernard-Soulier syndrome type C

“… 35 Ethical concerns discourage aggressive procedures to obtain HSCs from bone marrow from these patients, but some HSCs are present and could be isolated from non-mobilized peripheral blood. 64 , 65 , 66 Purified HSCs were exposed to R-GPIX to track lentiviral transduction. Despite the reduced number of starting HSCs, we could recover CD41-GPIX expression in EGFP + MKs and platelets.…”

Myelofibrosis and allogeneic transplantation: critical points and challenges

“…Moreover, in a recent retrospective study, a positive correlation has been found between peripheral blood CD34 cells and spleen length in both PMF and SMF, thus identifying a possible tool facilitating the assessment of spleen response more objectively than deep palpation of the abdomen ( 41 ).…”

Can circulating CD34+ cell count be used for the prognosis of myelofibrosis?

“…

We read with great interest the findings of the Iurlo et al 1 prospective cohort study, where the number of circulating CD34 + cells increased briefly and then returned to the pretreatment level during ruxolitinib treatment. Furthermore, the authors found a positive correlation between the change in the number of circulating CD34 + cells and the degree of splenomegaly during the first 6 months of treatment.A relative circulating CD34 + cell count of 0.015 × 10 9 /L is the most frequently used criterion to discriminate between myelofibrosis (MF) and other myeloproliferative neoplasms.

…”